Analysis and data insight

Other financings of public biotechnology companies in November 2019

December 6, 2019

No Comments

Private placements and other private financings of public biopharma companies in November 2019.

Completed and pending biopharma IPOs in November 2019

December 6, 2019

No Comments

Completed and pending initial public offerings by biopharma companies in November 2019.

Biopharma companies continue their strong momentum in November

December 3, 2019

By Peter Winter

No Comments

After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.

Indian pharma sector needs to learn from its competitors: report

December 3, 2019

By T.V. Padma

No Comments

NEW DELHI, India – While India is still an attractive prospect for investment in biotechnology, the country needs to learn from the successful examples of other countries, including its Asian biotech competitors, according to a new report.

In India, government steps up efforts to develop more TB testing and treatment

December 3, 2019

By T.V. Padma

No Comments

HYDERABAD – India, home to a quarter of the global tuberculosis (TB) cases, plans to enhance its capacity to fight TB drug resistance and bolster susceptibility testing under a new initiative launched by the Geneva-based nonprofit Foundation for Innovative New Diagnostics (FIND).

IPO class of 2019

Biopharma stocks up 26% on average since debut with Karuna as top performer

December 2, 2019

By Karen Carey

No Comments

With a 349% increase in stock price since its June debut on U.S. markets, Boston-based Karuna Therapeutics Inc. secures the title of best IPO performer so far in 2019. The stock skyrocketed in November following positive top-line phase II data of Karxt in acute psychosis in patients with schizophrenia, providing a potential read-through to larger indications such as Alzheimer’s disease and pain.